95 related articles for article (PubMed ID: 11593426)
1. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents.
Bergoglio V; Canitrot Y; Hogarth L; Minto L; Howell SB; Cazaux C; Hoffmann JS
Oncogene; 2001 Sep; 20(43):6181-7. PubMed ID: 11593426
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta.
Boudsocq F; Benaim P; Canitrot Y; Knibiehler M; Ausseil F; Capp JP; Bieth A; Long C; David B; Shevelev I; Frierich-Heinecken E; Hübscher U; Amalric F; Massiot G; Hoffmann JS; Cazaux C
Mol Pharmacol; 2005 May; 67(5):1485-92. PubMed ID: 15703384
[TBL] [Abstract][Full Text] [Related]
3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
4. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
[TBL] [Abstract][Full Text] [Related]
5. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
6. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
7. The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation.
Raaphorst GP; Cybulski SE; Sobol R; Ng CE
Anticancer Res; 2001; 21(3B):2079-83. PubMed ID: 11497301
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Qiu YY; Mirkin BL; Dwivedi RS
Cancer Detect Prev; 2005; 29(5):456-63. PubMed ID: 16185816
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
10. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
[TBL] [Abstract][Full Text] [Related]
11. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
13. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
16. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
17. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
19. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
Okuda T; Lin X; Trang J; Howell SB
Mol Pharmacol; 2005 Jun; 67(6):1852-60. PubMed ID: 15758147
[TBL] [Abstract][Full Text] [Related]
20. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
